Cibus Inc
NASDAQ:CBUS
Cibus Inc
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 228 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in developing and licensing plant traits to seed companies for royalties on seed sales. The firm is involved in gene-edited trait development, where plant traits (or specific genetic characteristics) that are indistinguishable from traits developed using traditional breeding are created using gene editing. Its patented RTDS technology platform includes the Trait Machine, which is a semi-automated stand-alone trait production facility. The Company’s Trait Machine materially changes the speed, breadth, and scale of trait development. The company is focused on the development of productivity traits and sustainable ingredients. The firm focuses on developing traits for addressing the sustainability challenges presented by climate change, disease, and pests.
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 228 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in developing and licensing plant traits to seed companies for royalties on seed sales. The firm is involved in gene-edited trait development, where plant traits (or specific genetic characteristics) that are indistinguishable from traits developed using traditional breeding are created using gene editing. Its patented RTDS technology platform includes the Trait Machine, which is a semi-automated stand-alone trait production facility. The Company’s Trait Machine materially changes the speed, breadth, and scale of trait development. The company is focused on the development of productivity traits and sustainable ingredients. The firm focuses on developing traits for addressing the sustainability challenges presented by climate change, disease, and pests.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
